2. Academic Validation
  3. Role of 68Ga-FAPI-04 PET/CT in the Initial Staging of Esophageal Cancer

Role of 68Ga-FAPI-04 PET/CT in the Initial Staging of Esophageal Cancer

  • Nuklearmedizin. 2023 Feb;62(1):38-44. doi: 10.1055/a-1984-8044.
Huipan Liu 1 2 3 4,  Xiao Yang 5,  Zhouxiang You 6,  Zhi Hu 6,  Yue Chen 1 2 3 4
Affiliations

Affiliations

  • 1 Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
  • 2 Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
  • 3 Academician (Expert) Workstation of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
  • 4 Institute of Nuclear Medicine, Southwest Medical University, Luzhou, China.
  • 5 Department of Nuclear Medicine, The Yibin No. 2 People's Hospital, Yibin, China.
  • 6 Department of Thoracic Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
PMID: 36746149 DOI: 10.1055/a-1984-8044
Abstract

Aim: To investigate the clinical value of 68Ga-FAPI-04 PET/CT for initial staging of esophageal Cancer.

Methods: A total of 44 newly diagnosed patients with esophageal Cancer were included in the analysis on the basis of postoperative pathology or clinical and radiologic follow-up.

Results: All primary lesions showed increased 68Ga-FAPI-04 uptake, with an SUVmax of 14.92 ± 6.91. A total of 561 lymph nodes were verified by surgery (507) or clinical and radiologic follow-up (54), of which 92 lymph nodes were diagnosed as showing metastases. Seventy-five lymph nodes with metastases showed positive findings on 68Ga-FAPI-04, with a diameter of about 1.06 ± 0.53 cm and SUVmax of 8.10±4.71. The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value for lymph node metastasis detection were 81.5%, 99.3%, 96.6%, 96.2%, and 96.5%, respectively.

Conclusion: 68Ga-FAPI-04 PET/CT showed good diagnostic performance in detecting lymph node metastases of esophageal Cancer.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-128643
    98.42%, FAP Inhibitor
    FAP